Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells

J Inorg Biochem. 2022 Jan:226:111657. doi: 10.1016/j.jinorgbio.2021.111657. Epub 2021 Nov 9.

Abstract

Angiogenin (Ang) is a potent angiogenic protein that is overexpressed in many types of cancer at concentration values correlated to the tumor aggressiveness. Here, by means of an integrated multi-technique approach based on crystallographic, spectrometric and spectroscopic analyses, we demonstrate that the anti-cancer drug oxaliplatin efficiently binds angiogenin. Microscopy cellular studies, carried out on the prostate cancer cell (PC-3) line , show that oxaliplatin inhibits the angiogenin prompting effect on cell proliferation and migration, which are typical features of angiogenesis process. Overall, our findings point to angiogenin as a possible target of oxaliplatin, thus suggesting a potential novel mechanism for the antineoplastic activity of this platinum drug and opening the avenue to novel approaches in the combined anti-cancer anti-angiogenic therapy.

Keywords: Angiogenesis; Confocal microscopy; Mass spectrometry; Platinum; Ribonuclease; X-ray crystallography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Movement / drug effects*
  • Cell Proliferation / drug effects*
  • Humans
  • Male
  • Neoplasm Proteins / metabolism*
  • Oxaliplatin / pharmacology*
  • PC-3 Cells
  • Prostatic Neoplasms* / drug therapy
  • Prostatic Neoplasms* / metabolism
  • Ribonuclease, Pancreatic / metabolism*

Substances

  • Neoplasm Proteins
  • Oxaliplatin
  • angiogenin
  • Ribonuclease, Pancreatic